Table 1.

Characteristics of patients from CALGB 50402 and CALGB 50701

Treatment protocol
CharacteristicsRituximab + epratuzimab (n = 55)Rituximab + galiximab (n = 46)Pa
Ethnicity1.00
 Caucasian50/53 (94.3%)45 (97.8%)
 Non-Caucasian3/53 (5.7%)1 (2.2%)
Median age, y (range)54 (32–90)58 (22–84)0.75
Female gender32 (58.1%)16 (34.8%)0.03
LDH > ULN5 (9.0%)7 (15.2%)0.37
“B” symptoms4/53 (7.5%)4/43 (9.3%)1.00
Follicular lymphoma stage0.74
 I
 II2 (3.6%)3/45 (6.7%)
 III18 (32.7%)16/45 (35.6%)
 IV35 (63.3%)26/45 (57.8%)
FLIPI0.97
 0–112/54 (22.2%)9/45 (20.0%)
 224/54 (44.4%)20/45 (44.4%)
 ≥318/54 (33.3%)16/45 (45.6%)
Histologic grade0.82
 Grade 130/53 (56.6%)27/45 (60.0%)
 Grade 220/53 (37.7%)17/45 (37.8%)
 Grade 3a3/53 (5.7%)1/45 (2.2%)
Bone marrow0.69
 Positive30 (54.6%)23 (50.0%)
 Negative25 (45.4%)23 (50.0%)
Bulky disease11/55 (20.0%)8/40 (20.0%)1.00
ECOG performance status0.05
 033 (60.0%)33/45 (73.3%)
 122 (40.0%)10/45 (22.2%)
 20 (0.0%)2/45 (4.4%)

Abbreviations: FLIPI, Follicular Lymphoma International Prognostic Index; LDH, lactic dehydrogenase; ULN, upper limit of normal.

  • aP values for the categorical variables were computed using the Fisher exact test; the Wilcoxon rank-sum test was used to compute age differences between groups.